Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype

Despite promising prior data on nintedanib, the addition of the drug to a standard regimen did not improve survival in patients with a specific type of lung cancer.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2OPYNcW